iwCLL 2023


Jointly provided by:

Target Audience

This activity is intended for community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who care for patients with CLL.

Educational Objectives

Upon completion of this activity, participants should be able to::
  • (YIM) Evaluate and interpret the clinical significance of emerging evidence regarding:
    • Factors contributing to the development of CLL
    • The diagnosis, prognosis, and initial treatment of CLL
    • Factors contributing to disease evolution and progression
    • Treatment of advanced disease
  • Evaluate the clinical trial results of current and emerging treatment strategies for patients with newly diagnosed CLL
  • Assess the latest safety and efficacy data of novel agents for patients with relapsed/refractory CLL
  • Identify best practices to achieve optimal outcomes among patients with CLL, including treating patients with high-risk disease, minimizing adverse events, and achieving minimal residual disease negativity
  • Discuss how genomics, proteomics, and metabolism of CLL affect the pathogenesis of disease
  • Compare and contrast approaches to the treatment of patients who develop Richter’s transformation
  • Recognize unique patient factors that influence the care of patients with CLL, including immunodeficiency and the risk of infections
  • Examine global perspectives and approaches for caring for patients with CLL


Disclosure of Conflicts of Interest

PACE requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Program Agenda

Americans with Disabilities Act

Event staff will be glad to assist you with any special needs (i.e., physical, dietary, etc). Please contact Sarah Rowan prior to the live event at

Fee Information

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE), Bio Ascend, LLC and iwCLL. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

PACE designates this live activity for a maximum of 22 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

International Physicians

The UEMS-EACCME® has had an agreement of mutual recognition of credits with the American Medical Association (AMA) for live educational events and for e-learning materials since the year 2000. The agreement was renewed in 2022 for another 4 years. Upon completion of this activity, PACE will provide European physicians with a certificate of completion that lists the number of AMA PRA Category 1 Credits™ and a statement that refers to the AMA agreement with the EACCME.

Evaluation/Claim CE or Certificate

Please navigate to either the event website or mobile APP in order to complete your evaluation and receive CE credit/a certificate of participation.
Log in with your username/email and Access Key; the Access Key is the same for both the website and the APP
Scroll to the bottom to the Evaluation/Claim CE icon (website) or CE Information tile (APP)

Follow the instructions for credit:
Complete all session evaluations for which you attended
Complete the mandatory Overall Conference Evaluation
Once all of your tasks are complete, you will be able to download your certificate(s) In order to receive your credit/certificate, all evaluations must be completed by November 10, 2023. For any questions, please email